Chanan-Khan A - Search Results

1

CD38 as a multifaceted immunotherapeutic target in CLL.

Paulus A, Malavasi F, Chanan-Khan A. Paulus A, et al. Leuk Lymphoma. 2022 Oct;63(10):2265-2275. doi: 10.1080/10428194.2022.2090551. Epub 2022 Aug 17. Leuk Lymphoma. 2022. PMID: 35975791 Review.

2

Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.

Miller KC, Padmanabhan S, Dimicelli L, Depaolo D, Landrigan B, Yu J, Doran V, Marshal P, Chanan-Khan A. Miller KC, et al. Leuk Lymphoma. 2006 Nov;47(11):2339-43. doi: 10.1080/10428190600799631. Leuk Lymphoma. 2006. PMID: 17107907 Clinical Trial.

3

The many lives of thalidomide.

Patel MP, Chanan-Khan AA. Patel MP, et al. Leuk Lymphoma. 2009 Jun;50(6):861-2. doi: 10.1080/10428190902964784. Leuk Lymphoma. 2009. PMID: 19479617 No abstract available.

4

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.

Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Sher T, et al. Leuk Lymphoma. 2010 Jan;51(1):85-8. doi: 10.3109/10428190903406806. Leuk Lymphoma. 2010. PMID: 20055660 Clinical Trial.

5

Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma.

Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K, Lee K, Chanan-Khan AA. Paulus A, et al. J Clin Oncol. 2011 Jan 20;29(3):e47-9. doi: 10.1200/JCO.2010.30.3370. Epub 2010 Oct 18. J Clin Oncol. 2011. PMID: 20956627 No abstract available.

6

Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia.

Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Advani PP, et al. Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):765-74. doi: 10.1517/17425255.2011.579105. Epub 2011 Apr 27. Expert Opin Drug Metab Toxicol. 2011. PMID: 21521129 Review.

7

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Chanan-Khan AA, et al. Br J Haematol. 2011 Nov;155(4):457-67. doi: 10.1111/j.1365-2141.2011.08882.x. Epub 2011 Oct 20. Br J Haematol. 2011. PMID: 22010965 Free PMC article. Clinical Trial.

8

Targeted treatment for chronic lymphocytic leukemia.

Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A. Masood A, et al. Onco Targets Ther. 2011;4:169-83. doi: 10.2147/OTT.S7173. Epub 2011 Nov 4. Onco Targets Ther. 2011. PMID: 22162923 Free PMC article.

9

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.

Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Masood A, et al. Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15. Br J Haematol. 2012. PMID: 22171982 Free article. Clinical Trial.

10

Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.

Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Swaika A, et al. J Support Oncol. 2012 Jul-Aug;10(4):155-9. doi: 10.1016/j.suponc.2011.10.006. Epub 2012 Jan 4. J Support Oncol. 2012. PMID: 22222250

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page